In Vitro Antibacterial Activity Against Staphylococcus Aureus, Propionibacterium Acnes and Pseudomonas Aeruginosa
Total Page:16
File Type:pdf, Size:1020Kb
FULL PAPER Rational design and synthesis of modified teixobactin analogues: in vitro antibacterial activity against Staphylococcus aureus, Propionibacterium acnes and Pseudomonas aeruginosa [a] [b] *[a] Vivian Ng, Sarah A. Kuehne and Weng C. Chan Abstract: Teixobactin, a recently discovered depsipeptide that binds demonstrated excellent bactericidal activity against methicillin- to bacterial lipid II and lipid III, provides a promising molecular resistant Staphylococcus aureus (MRSA) which is associated scaffold for the design of new antimicrobials. Herein, we describe the with a wide range of infections in both the community (e.g. synthesis and antimicrobial evaluation of systematically modified cellulitis, abscesses) and the hospital settings (e.g. bacteraemia, teixobactin analogues. The replacement of Ile11 residue with aliphatic pneumonia).[4–6] Vancomycin is currently the last line of defence isosteres, the modification of the guanidino group at residue 10 and against MRSA infections but strains with reduced susceptibility the introduction of a rigidifying residue, dehydroamino acid into the to this antibiotic have surfaced.[7–10] Teixobactin offers a potential macrocyclic ring generated useful structure-activity information. solution to this predicament since it remains effective against Extensive antimicrobial susceptibility assessment against a panel of MRSA, as well as vancomycin-intermediate S. aureus (VISA) clinically relevant Staphylococcus aureus and Propionibacterium due to its unique mode of action.[4] It has been shown to acnes led to the identification of a new lead compound, synergistically block the biosyntheses of peptidoglycan and [Arg(Me)10,Nle11]teixobactin 63, with excellent bactericidal activity teichoic acid, thereby resulting in a weakened cell wall and (MIC 2–4 μg/mL). Significantly, the antimicrobial activity of several of autolysin-mediated cell lysis.[4,11] the teixobactin analogues against the pathogenic Gram-negative Teixobactin 1 is also a potent antimicrobial against another Pseudomonas aeruginosa was ‘restored’ when combined with sub- human skin commensal, Propionibacterium acnes.[4] This Gram- MIC concentration of the outer membrane-disruptive antibiotic, positive anaerobe is commonly associated with acnes colistin. The antimicrobial effectiveness of [Tfn10,Nle11]teixobactin 66 vulgaris.[12] In recent years, however, it is increasingly (32 μg/mL)-colistin (2 μg/mL; 0.5x MIC) combination against P. recognised as an opportunistic pathogen that can cause aeruginosa PAO1 reveals, for the first time, an alternative invasive infections, especially those associated with medical therapeutic option in the treatment of Gram-negative infections. implants.[13,14] There have been several reports on the isolation of P. acnes from prosthetic joints, cardiovascular devices and ophthalmic implants.[14–18] To aggravate matters, the widespread use of antibiotics to treat acne vulgaris has led to the emergence Introduction of P. acnes strains that are resistant to numerous antibiotics, including the macrolides, tetracycline and metronidazole.[13,19–22] Life-saving antibiotics are rapidly losing the race against the The need for novel antimicrobials is therefore more pressing development of bacterial resistance to most, if not all, antibiotics. than ever. It is hoped that teixobactin and its analogues may The resultant health and financial implications have spurred the serve as a timely solution to this clinically important pathogen. deployment of antimicrobial stewardship programmes across the globe to ensure evidence-based prescribing of antibiotics that are still effective.[1–3] Meanwhile, scientists are working hand-in- hand to tackle the resistance crisis through drug discovery and development initiatives. Natural antimicrobial peptides serve as invaluable molecular scaffolds for the development of the next generation of antimicrobial therapeutics. The recently discovered depsipeptide, teixobactin 1 (Figure 1), has great potential as a lead compound due to its favourable potency against many Structure of teixobactin and the four sites (blue) of modification Gram-positive pathogens.[4] Among them, teixobactin has Figure 1. 1 presented in this work. Teixobactin 1, comprised of a 13-membered depsipeptide [a] V. Ng, Dr W.C. Chan core and a tethered linear heptapeptide, offers multiple sites for School of Pharmacy, Centre for Biomolecular Sciences, synthetic modifications to improve its potency and efficacy. In University of Nottingham, University Park, Nottingham, U.K., NG7 2RD. less than three years since its discovery, more than a hundred E-mail: [email protected] analogues have been synthesized by various research groups in [b] Dr. S.A. Kuehne the hope of elucidating its structure-activity relationships School of Dentistry, and Institute for Microbiology and Infection, (SARs).[23–37] The biological activities of these analogues and the University of Birmingham, Birmingham, U.K., B5 7EG. different synthetic strategies reported have been comprehensively reviewed.[38,39] X-ray crystallographic, Supporting information for this article is given via a link at the end of molecular dynamic and NMR structural studies have also been the document. conducted to construct possible binding models of the native FULL PAPER peptide and its analogues.[26,27,40] Additionally, in a recent mini- review, we provided an insight into the structural similarities of teixobactin with other lipid II inhibitors.[41] Together, these resources provide tremendous information that could aid the design of optimised analogues. Early synthetic endeavours focused primarily on the exocyclic tail and the backbone stereochemistry of the native peptide. The replacement of any D-amino acid residues with its L-counterparts abolished activity, suggesting a significant contribution of these residues for the optimal conformation of teixobactin.[25,26,30] Yang et al. further demonstrated the importance of the N-terminal tail as the removal of the first five residues detrimentally affected antimicrobial potency.[24] Teixobactin appears to bind to the pyrophosphate and N- acetylmuramic acid amino sugar of lipid II. As such, its cyclic ring is believed to act as the main site of recognition.[4] With these considerations in mind, we have developed a series of analogues with modifications mainly on the macrocyclic core to Scheme 1. An optimized synthesis of Ni(II)-Gly-(S)-2-[N-(N- examine the significance of hydrophobicity at position 11, the benzylprolyl)amino]-benzophenone (BPB). cationic feature of the guanidino group at position 10, and the effect of introducing conformational rigidity at position 9. The N- Thus, using the protocol developed by Belokon et al., the Me-D-Phe1 was also replaced with D-Trp in an attempt to first step in the synthesis progressed smoothly to give N- investigate the contribution of the phenyl group. benzylated L-proline (S)-(3) in high yield.[43] Although the Apart from replacing the Ile residue at position 11 with condensation between (S)-(3) and 2-aminobenzophenone did readily available aliphatic isosteres, we sought to investigate the not proceed to completion, a reasonable yield of 45–60 % was effect of introducing fluorine atoms and unsaturated side-chain obtained. To our dismay, the use of KOH in the final step, i.e. at this position. Thus, Fmoc-(S)-6,6,6-trifluoronorleucine-OH the transformation of (S)-4 to (S)-5, gave a disappointing 50 % (Fmoc-Tfn-OH) and Fmoc-(S)-homoallylglycine-OH (Fmoc-Hag- recovery of (S)-5 after three recrystallizations. A review of the OH) were synthesized and their preparation will be discussed literature indicated that K2CO3 was previously employed by prior to the synthesis of the teixobactin analogues. All analogues Soloshonok and co-workers to prepare a closely related Schiff were extensively evaluated for their antimicrobial activity against base,[44] thereby suggesting that this alternative base could be both S. aureus and P. acnes. Thus far, most biological more effective for synthesizing (S)-5. Gratifyingly, K2CO3 (20 assessments of reported teixobactin analogues are focused on equiv.) drove the final reaction step to completion within an hour S. aureus and only the activity of the native peptide is known and (S)-5 was recrystallized from MeOH/H2O in >85 % yield. against P. acnes. Herein, we report detailed antimicrobial activity of teixobactin analogues against several P. acnes strains. Although teixobactin and analogues thereof are considered inactive against Gram-negative bacteria (MIC >256 μg/mL), the effect of using teixobactin analogues in combination with colistin was also investigated against the Gram-negative pathogen Pseudomonas aeruginosa. Results and Discussion Synthesis of Fmoc-(S)-6,6,6-trifluoronorleucine-OH and Fmoc-(S)-homoallylglycine-OH An operationally simple and cost-effective approach for the Scheme 2. An optimised synthesis of Fmoc-6,6,6-trifluoronorleucine-OH. asymmetric synthesis of Fmoc-Tfn-OH (S)-7 and Fmoc-Hag-OH (S)-9 is by alkylation of an achiral auxiliary reagent Ni(II)-glycine Having successfully prepared the Ni(II)-Schiff base (S)-5, Schiff base (S)-5.[42,43] The Ni(II)-complex (S)-5 was synthesized we then sought to optimise the alkylation of the complex with in large scale in three straightforward steps (Scheme 1). The 1,1,1-trifluoro-4-iodobutane (Scheme 2). Wang et al. have coordination of Ni(II) ion to the glycine greatly increased the previously reported a high diastereoselectivity (97%) was [45] acidity of the α-proton, enabling